Gingold N, Butoianu E, Nicoară S
Med Interne. 1978 Jul-Sep;16(3):291-6.
A new therapeutic schedule for preventive therapy of the central nervous system (CNS) complications by intrathecal (i.t.) injections of methotrexate (MTX) was applied in two groups of 6 and respectively 13 adults with acute lymphoblastic or non-lymphoblastic leukemias. Instead of starting this treatment only in the remission stage, i.t. MTX was given from the very beginning of cytostatic therapy. In most of the patients this drug proved to be effective in preventing CNS involvement. In some cases, however, it was not well, tolerated owing probably to a neurotoxic effect. This suggested continuation of the study with Ara-C.
两组分别为6名和13名患有急性淋巴细胞白血病或非淋巴细胞白血病的成年人采用了一种新的治疗方案,即通过鞘内注射甲氨蝶呤(MTX)来预防中枢神经系统(CNS)并发症。鞘内注射MTX并非仅在缓解期开始治疗,而是从细胞抑制疗法一开始就进行给药。在大多数患者中,这种药物被证明对预防CNS受累有效。然而,在某些情况下,由于可能的神经毒性作用,其耐受性不佳。这表明要用阿糖胞苷继续进行研究。